Rossari Biotech Limited Q1 FY27 Earnings Call Summary

Event Participants

Executives

3 Edward Menezes, Ketan Sablok, Sunil Chari

Analysts

6 Disha Bhordia, Divyansh Jaju, Rohan Picha, Rohit Nagraj, Sanjesh Jain, Vinith Jain

Financials & KPIs

Geographic & Segment Commentary

• HPPC (Home, Personal & Performance Care): Crossed ₹550 crore quarterly revenue with ~28% YoY growth. Management is broadening presence in personal care, pharma applications, agrochemicals, and performance chemicals, leveraging formulation expertise and improving ethoxylation capacity utilisation.

• TSC (Textile Specialty Chemicals): Grew ~28% YoY. Launched a dedicated Fibre Chemicals Division to expand capabilities across the fibre-to-fibre value chain, supported by application-driven R&D and manufacturing platform.

• AHN (Animal Health & Nutrition): Grew ~28% YoY, driven by trace minerals, vitamin premixes, and enzyme premixes. The vitamin premix plant has become operational and is contributing to topline.

• International / Exports: Exports grew 21% YoY to ₹160 crore (23-24% of revenue). The greenfield Thailand blending plant (investment ₹10-15 crore) generated ₹2-3 crore in Q1 and is ramping up across textile products, with AHN and HPPC molecules planned. The KSA project remains in exploratory phase with no finalised land/feedstock allocation.

• Institutional & Consumer (B2C): Growth flat YoY with losses moderating on cost optimisation and mix improvement. Management is evaluating exit of the B2C consumer business while retaining the institutional cleaning business, which is the more profitable core cleaning chemicals operation.

Company-Specific & Strategic Commentary

• R&D Platform: New R&D centre commissioned in Q4 FY26 is progressively ramping up, integrating research, product development, and application capabilities to accelerate new product development and faster commercialisation.

• Product Innovation: NMMO, MDEA, spray-cooled powders, biosurfactants, fibre finishes, and the vitamin premix plant are contributing "handsomely" to topline. Non-EO products (esters, NMM, NFM, agro adjuvants) are gaining traction and offsetting EO supply constraints.

• Portfolio Rationalisation: Exiting B2C consumer business (releases 2-3% EBITDA margin); monetising non-core assets — Andheri office sold for ₹10.5 crore in Q1, Kanjurmarg office for ~₹24 crore in Q4 FY26. ~₹50 crore debt attached to the institutional/consumer complex.

• KSA Greenfield Project: Significant strategic opportunity with access to globally competitive raw materials and petrochemical ecosystem. Discussions ongoing with KSA ministry, suppliers, and consultants; ~1.5-year gestation from announcement to first production; pre-operative expenses expected for ~2 years.

• CAPEX Discipline: India CAPEX slowed to calibrated spends on new molecules only (pharma, aroma chemicals); focus shifted to optimising utilisation of the expanded asset base.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

Margin Trajectory & Improvement Path

• Question: With EBITDA margin stuck at ~11.6% for 4-5 quarters, which segments will drive margin growth? (Divyansh Jaju)
• Answer: Improvements will come from capacity utilisation, exiting low-margin businesses, and new higher-margin areas like pharma and aroma chemicals. New products (NMMO, MDEA, spray-cooled powders, fibre finishes, vitamin premixes) are already contributing to topline; 2-3 years needed for full capacity utilisation. (Ketan Sablok, Edward Menezes)

Raw Material Pass-Through & Margin Base

• Question: Can RM price hikes be passed on, and is 11.6% the floor? (Disha Bhordia)
• Answer: RM pass-through is not a concern; the real issue is freight/insurance cost and vessel unavailability creating margin loss. Management confirmed 11.6% can be treated as the base level going forward. (Sunil Chari, Ketan Sablok)

FY27 Revenue Guidance

• Question: You guided ~15% growth for FY27, but Q1 grew 28% — should guidance be revised up? (Disha Bhordia)
• Answer: No — management sticks to ~15% annualised topline growth given global volatility, freight spikes, and one-off cost hits. The Thailand plant and new capacities are just coming on stream, and geopolitical unpredictability makes quarterly prediction difficult. (Sunil Chari, Ketan Sablok)

B2C Exit — Debt & Margin Impact

• Question: What is the debt and EBITDA impact of exiting the B2C business? (Vinith Jain)
• Answer: ~₹50 crore debt is attached to the institutional/consumer complex. Exiting the consumer (B2C) part will release at least 2-3% EBITDA margin; the institutional cleaning business will be retained as it is the profitable core cleaning chemicals business. (Ketan Sablok)

Volume vs Price & Non-EO Growth Levers

• Question: What is the volume vs price split of Q1 growth, and how do you grow without EO? (Sanjesh Jain)
• Answer: Volume grew ~10%, with the balance from pricing. Growth is being driven by non-EO products — esters, NMM, NFM, NMMO, agro adjuvants, trace minerals, vitamin/enzyme premixes — and by reformulating products with lower EO and higher non-EO content. (Ketan Sablok, Sunil Chari)

Phenol Hit & Sector Comparison

• Question: Domestic-focused chemical companies saw spread expansion in Q1 — why not Rossari? (Sanjesh Jain)
• Answer: Single-molecule players (soda ash, acetic acid) benefited; specialty chemicals took RM hits. Phenol alone cost ~₹5 crore — contracted Chinese shipments arrived ~1 month late, forcing market purchases at elevated prices. Management views this as a one-off, with phenol pricing back to earlier levels. (Sunil Chari, Ketan Sablok)

Pharma Business Scale-up

• Question: How will pharma revenue scale, given it is higher margin? (Disha Bhordia)
• Answer: Compliance work (plant and customer end) should be largely done by Q2-Q3; new pharma products have ₹30-50 crore revenue potential in FY27, mostly H2. Total pharma business target is ₹70-75 crore this year vs ₹50+ crore last year. (Ketan Sablok, Sunil Chari)

Thailand Plant Contribution

• Question: What is the Thailand plant's Q1 contribution, utilisation, and peak revenue? (Disha Bhordia)
• Answer: Q1 revenue of ₹2-3 crore, ramping up; currently textile products, with AHN and HPPC molecules planned later. Investment is only ₹10-15 crore — it is a small formulation unit focused on proximity to Southeast Asian customers. (Ketan Sablok, Sunil Chari)

KSA Project — Gestation & Scope

• Question: What is the timeline from investment announcement to production, and what chemistries? (Rohit Nagraj, Disha Bhordia)
• Answer: ~1.5 years to first production after announcement. The project will be a mix of EO and non-EO products, choosing whichever offers higher margins or realisations. Land and feedstock allocation are still under survey; nothing finalised. (Sunil Chari, Ketan Sablok)

Debt & Interest Cost

• Question: Why has interest cost increased, and what is the current debt level? (Rohit Nagraj)
• Answer: Net debt is ₹248 crore, down from ~₹280 crore in March. Interest is higher because term-loan interest on CAPEX (previously capitalised) now flows through the P&L. Finance cost should run at ₹9-10 crore quarterly going forward. Andheri office sold for ₹10.5 crore (profit in other income); Kanjurmarg office fetched ~₹24 crore in Q4. (Ketan Sablok)

EO Supply & Margin Impact

• Question: Once EO supply is secured, will gross margins improve? (Rohan Picha)
• Answer: Margin improvement depends on world EO pricing (sole Indian supplier, no negotiation scope, but fair and globally competitive pricing) and product mix. Current EO capacity is ~100% utilised except batch reactors; the continuous ethoxylation (MDEA) plant ramp-up over the next 12 months should drive higher margins. (Sunil Chari)

Key Takeaway

Rossari delivered record Q1 FY27 results with revenue of ₹697.2 crore (+28% YoY) and EBITDA of ₹80.6 crore (+18.7% YoY), as HPPC (₹550+ crore), TSC, and AHN each grew 28% YoY and exports rose 21% to ~₹160 crore. EBITDA margin of 11.6% declined 90 bps YoY, pressured by institutional/consumer losses, a ~₹5 crore phenol cost hit, and freight volatility; management confirmed 11.6% as the base and targets 15%+ steady-state margins in ~2 years via B2C exit (releasing 2-3% EBITDA), product mix gains, and capacity utilisation. FY27 revenue guidance of ~15% was retained despite the strong Q1, with EO supply expected by December 2026 to drive FY28 acceleration. Strategic priorities include pharma scale-up to ₹70-75 crore, Thailand plant ramp-up, the KSA project (1.5-year gestation post-announcement), and calibrated CAPEX, with net debt down to ₹248 crore. Key watch points remain geopolitical freight shocks, EO supply timing, and execution of the B2C exit and KSA initiative.